Telemedicine: The future of clinical trials?

Telemedicine – or remote visits – has traditionally been used for patient-physician consultations and the delivery of health care. Today, the value of telemedicine in clinical trials is creating a buzz. With the promise of greater access to research and reduced attrition, what else is driving pharma’s move towards decentralized trials?  For Boehringer Ingelheim, patient-centricity is at the heart of its drive to conducting decentralized clinical research, says Brandon Maggio, Associate Director. “A patient’s geographic location and/or socioeconomic status is one of the largest barriers to enrollment and retention in clinical trials. Telemedicine addresses this while also increasing the probability of improved patient diversity. This gives a more accurate representation of a given diseas e population and how an investigational medicinal product will act within that population.” Janssen ’s interest is driven by the direct-to-patient model’s promise to improve the diversity of trial participants and patient access to clinical trials, says Dimitri Talantov, Senior Medical Director, Janssen Clinical Innovation. “Additionally, by improving clinical operational efficiency, novel m edicines make it to patients faster,” he adds.  Greater access to trials and a faster path to market benefits both pharma and patients. But, to claim this model of clinical research is patient-centric requires more evidence of patient value. So, just how patient-centric is telemedi...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news